Form 4: Mirum CFO Sells Shares for Tax Obligations

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, acquired shares from vested performance restricted stock units and subsequently sold a portion to cover tax withholding obligations.

Summary

• Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, Inc., acquired 13,334 shares of common stock on March 15, 2026, upon the vesting of performance restricted stock units.
• On March 16, 2026, Bjerkholt sold 7,287 shares of common stock at a price of $91.9779 per share.
• The sale of shares was conducted to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
• Following these transactions, Bjerkholt beneficially owns 49,788 shares of common stock directly.
• An additional 6,666 performance restricted stock units remain, scheduled to vest on March 15, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is routine for executive compensation, involving the vesting of RSUs and a subsequent sale to cover tax obligations, rather than a discretionary sale indicating a change in sentiment.

Positives

• Vesting of performance restricted stock units indicates the achievement of performance milestones or continued employment.
• The acquisition of 13,334 shares increases the CFO's direct ownership, albeit temporarily before the tax-related sale.

Negatives

• A significant portion (7,287 shares) of the newly vested shares were immediately sold, reducing the net increase in direct ownership.

Future Outlook

The filing indicates that 6,666 performance restricted stock units are scheduled to vest on March 15, 2027.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to RSU vesting and subsequent tax-related sales, are common occurrences for executives in publicly traded biotechnology and pharmaceutical companies like Mirum Pharmaceuticals. These transactions typically reflect compensation structures rather than a change in management's outlook on the company's prospects, especially when explicitly stated as tax-related.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and does not indicate a material change in company fundamentals or management's long-term view, thus minimal direct impact on shareholders beyond the reported transaction details.

Next Steps

• Vesting of the remaining 6,666 performance restricted stock units on March 15, 2027.

Key Dates

Recommendation

The filing details a routine insider transaction where the CFO acquired shares through RSU vesting and immediately sold a portion to cover tax obligations. This is a common practice and does not reflect a discretionary sale or a change in the company's fundamental outlook. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, Eric Bjerkholt, CFO, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding